303 related articles for article (PubMed ID: 30760453)
21. Allogeneic Hemopoietic Stem Cell Transplantation for Myelofibrosis: 2021.
Bacigalupo A; Innocenti I; Rossi E; Sora F; Galli E; Autore F; Metafuni E; Chiusolo P; Giammarco S; Laurenti L; Benintende G; Sica S; De Stefano V
Front Immunol; 2021; 12():637512. PubMed ID: 34017327
[TBL] [Abstract][Full Text] [Related]
22. Controversies and dilemmas in allogeneic transplantation for myelofibrosis.
Shanavas M; Gupta V
Best Pract Res Clin Haematol; 2014 Jun; 27(2):165-74. PubMed ID: 25189727
[TBL] [Abstract][Full Text] [Related]
23. Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management.
Tefferi A
Am J Hematol; 2021 Jan; 96(1):145-162. PubMed ID: 33197049
[TBL] [Abstract][Full Text] [Related]
24. Impact of High-Molecular-Risk Mutations on Transplantation Outcomes in Patients with Myelofibrosis.
Tamari R; Rapaport F; Zhang N; McNamara C; Kuykendall A; Sallman DA; Komrokji R; Arruda A; Najfeld V; Sandy L; Medina J; Litvin R; Famulare CA; Patel MA; Maloy M; Castro-Malaspina H; Giralt SA; Weinberg RS; Mascarenhas JO; Mesa R; Rondelli D; Dueck AC; Levine RL; Gupta V; Hoffman R; Rampal RK
Biol Blood Marrow Transplant; 2019 Jun; 25(6):1142-1151. PubMed ID: 30625392
[TBL] [Abstract][Full Text] [Related]
25. Allogeneic stem cell transplantation for myelofibrosis patients aged ≥65 years.
Daghia G; Zabelina T; Zeck G; von Pein UM; Christopeit M; Wolschke C; Ayuk F; Kröger N
Eur J Haematol; 2019 Oct; 103(4):370-378. PubMed ID: 31306511
[TBL] [Abstract][Full Text] [Related]
26. Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome.
Shaffer BC; Ahn KW; Hu ZH; Nishihori T; Malone AK; Valcárcel D; Grunwald MR; Bacher U; Hamilton B; Kharfan-Dabaja MA; Saad A; Cutler C; Warlick E; Reshef R; Wirk BM; Sabloff M; Fasan O; Gerds A; Marks D; Olsson R; Wood WA; Costa LJ; Miller AM; Cortes J; Daly A; Kindwall-Keller TL; Kamble R; Rizzieri DA; Cahn JY; Gale RP; William B; Litzow M; Wiernik PH; Liesveld J; Savani BN; Vij R; Ustun C; Copelan E; Popat U; Kalaycio M; Maziarz R; Alyea E; Sobecks R; Pavletic S; Tallman M; Saber W
J Clin Oncol; 2016 Jun; 34(16):1864-71. PubMed ID: 27044940
[TBL] [Abstract][Full Text] [Related]
27. Myeloablative and Reduced-Intensity Conditioned Allogeneic Hematopoietic Stem Cell Transplantation in Myelofibrosis: A Retrospective Study by the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.
McLornan D; Szydlo R; Koster L; Chalandon Y; Robin M; Wolschke C; Beelen D; Socié G; Bornhäuser M; Angelucci E; Niederwieser D; Gerbitz A; Finke J; Vitek A; Itälä-Remes M; Radujkovic A; Kanz L; Potter V; Chevallier P; Stelljes M; Petersen E; Robinson S; Poiré X; Klyuchnikov E; Hernández-Boluda JC; Czerw T; Hayden P; Kröger N; Yakoub-Agha I
Biol Blood Marrow Transplant; 2019 Nov; 25(11):2167-2171. PubMed ID: 31284069
[TBL] [Abstract][Full Text] [Related]
28. MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis.
Guglielmelli P; Lasho TL; Rotunno G; Mudireddy M; Mannarelli C; Nicolosi M; Pacilli A; Pardanani A; Rumi E; Rosti V; Hanson CA; Mannelli F; Ketterling RP; Gangat N; Rambaldi A; Passamonti F; Barosi G; Barbui T; Cazzola M; Vannucchi AM; Tefferi A
J Clin Oncol; 2018 Feb; 36(4):310-318. PubMed ID: 29226763
[TBL] [Abstract][Full Text] [Related]
29. Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type.
Bacigalupo A; Soraru M; Dominietto A; Pozzi S; Geroldi S; Van Lint MT; Ibatici A; Raiola AM; Frassoni F; De Stefano F; Verdiani S; Casarino L; Barosi G
Bone Marrow Transplant; 2010 Mar; 45(3):458-63. PubMed ID: 19718055
[TBL] [Abstract][Full Text] [Related]
30. Family Mismatched Allogeneic Stem Cell Transplantation for Myelofibrosis: Report from the Chronic Malignancies Working Party of European Society for Blood and Marrow Transplantation.
Raj K; Eikema DJ; McLornan DP; Olavarria E; Blok HJ; Bregante S; Ciceri F; Passweg J; Ljungman P; Schaap N; Carlson K; Zuckerman T; de Wreede LC; Volin L; Koc Y; Diez-Martin JL; Brossart P; Wolf D; Blaise D; Bartolomeo PD; Vitek A; Robin M; Yakoub-Agha I; Chalandon Y; Kroger N
Biol Blood Marrow Transplant; 2019 Mar; 25(3):522-528. PubMed ID: 30408564
[TBL] [Abstract][Full Text] [Related]
31. Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management.
Tefferi A
Am J Hematol; 2016 Dec; 91(12):1262-1271. PubMed ID: 27870387
[TBL] [Abstract][Full Text] [Related]
32. Rapid regression of bone marrow fibrosis after dose-reduced allogeneic stem cell transplantation in patients with primary myelofibrosis.
Kröger N; Thiele J; Zander A; Schwerdtfeger R; Kobbe G; Bornhäuser M; Bethge W; Schubert J; de Witte T; Kvasnicka HM;
Exp Hematol; 2007 Nov; 35(11):1719-22. PubMed ID: 17976523
[TBL] [Abstract][Full Text] [Related]
33. The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation.
Scott BL; Gooley TA; Sorror ML; Rezvani AR; Linenberger ML; Grim J; Sandmaier BM; Myerson D; Chauncey TR; Storb R; Buxhofer-Ausch V; Radich JP; Appelbaum FR; Deeg HJ
Blood; 2012 Mar; 119(11):2657-64. PubMed ID: 22234678
[TBL] [Abstract][Full Text] [Related]
34. Allogeneic stem cell transplant vs.Janus kinase inhibition in the treatment of primary myelofibrosis or myelofibrosis after essential thrombocythemia or polycythemia vera.
Alchalby H; Kröger N
Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S36-41. PubMed ID: 25486953
[TBL] [Abstract][Full Text] [Related]
35. Prognosis in transplant-eligible patients with agnogenic myeloid metaplasia: a simple CBC-based scoring system.
Dingli D; Schwager SM; Mesa RA; Li CY; Tefferi A
Cancer; 2006 Feb; 106(3):623-30. PubMed ID: 16369987
[TBL] [Abstract][Full Text] [Related]
36. Optimized EBMT transplant-specific risk score in myelodysplastic syndromes after allogeneic stem-cell transplantation.
Gagelmann N; Eikema DJ; Stelljes M; Beelen D; de Wreede L; Mufti G; Knelange NS; Niederwieser D; Friis LS; Ehninger G; Nagler A; Yakoub-Agha I; Meijer E; Ljungman P; Maertens J; Kanz L; Lopez-Corral L; Brecht A; Craddock C; Finke J; Cornelissen JJ; Bernasconi P; Chevallier P; Sierra J; Robin M; Kröger N
Haematologica; 2019 May; 104(5):929-936. PubMed ID: 30655377
[TBL] [Abstract][Full Text] [Related]
37. Splenic irradiation as a component of a reduced-intensity conditioning regimen for hematopoietic stem cell transplantation in myelofibrosis with massive splenomegaly.
Ito T; Akagi K; Kondo T; Kawabata H; Ichinohe T; Takaori-Kondo A
Tohoku J Exp Med; 2012 Dec; 228(4):295-9. PubMed ID: 23117264
[TBL] [Abstract][Full Text] [Related]
38. Is allogeneic stem cell transplantation for myelofibrosis still indicated at the time of molecular markers and JAK inhibitors era?
Lestang E; Peterlin P; Le Bris Y; Dubruille V; Delaunay J; Godon C; Theisen O; Blin N; Mahe B; Gastinne T; Garnier A; Touzeau C; Voldoire M; Bene MC; Le Gouill S; Milpied N; Mohty M; Moreau P; Guillaume T; Chevallier P
Eur J Haematol; 2017 Jul; 99(1):60-69. PubMed ID: 28370306
[TBL] [Abstract][Full Text] [Related]
39. Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis.
Michiels JJ; Kutti J; Stark P; Bazzan M; Gugliotta L; Marchioli R; Griesshammer M; van Genderen PJ; Brière J; Kiladjian JJ; Barbui T; Finazzi G; Berlin NI; Pearson TC; Green AC; Fruchtmann SM; Silver RT; Hansmann E; Wehmeier A; Lengfelder E; Landolfi R; Kvasnicka HM; Hasselbalch H; Cervantes F; Thiele J
Neth J Med; 1999 Feb; 54(2):46-62. PubMed ID: 10079679
[TBL] [Abstract][Full Text] [Related]
40. Indication and management of allogeneic haematopoietic stem-cell transplantation in myelofibrosis: updated recommendations by the EBMT/ELN International Working Group.
Kröger N; Bacigalupo A; Barbui T; Ditschkowski M; Gagelmann N; Griesshammer M; Gupta V; Hamad N; Harrison C; Hernandez-Boluda JC; Koschmieder S; Jain T; Mascarenhas J; Mesa R; Popat UR; Passamonti F; Polverelli N; Rambaldi A; Robin M; Salit RB; Schroeder T; Scott BL; Tamari R; Tefferi A; Vannucchi AM; McLornan DP; Barosi G
Lancet Haematol; 2024 Jan; 11(1):e62-e74. PubMed ID: 38061384
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
